247023-19-4

Basic information

• Product Name: (2-BENZYLOXY-PHENYL)-HYDRAZINE
• Synonyms: VITAS-BB TBB000061;(2-BENZYLOXY-PHENYL)-HYDRAZINE
• CAS NO: 247023-19-4
• Molecular Formula: C13H14N2O
• Molecular Weight: 214.26
• Product Categories: pharmacetical
• Mol File: 247023-19-4.mol

Chemical Properties

• Boiling Point: 384.5±25.0 °C(Predicted)
• Appearance: /
• Density: 1.185±0.06 g/cm3(Predicted)
• PKA: 5.52±0.50(Predicted)
• CAS DataBase Reference: (2-BENZYLOXY-PHENYL)-HYDRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: (2-BENZYLOXY-PHENYL)-HYDRAZINE(247023-19-4)
• EPA Substance Registry System: (2-BENZYLOXY-PHENYL)-HYDRAZINE(247023-19-4)

Safety Data

• Hazardous Substances Data: 247023-19-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2-BENZYLOXY-PHENYL)-HYDRAZINE is used as a building block for the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new and effective compounds in these fields.
Used in Medicinal Chemistry:
(2-BENZYLOXY-PHENYL)-HYDRAZINE is used as a starting material for the synthesis of bioactive molecules, potentially leading to the discovery of new drugs with therapeutic benefits.
Used in Anticancer Applications:
(2-BENZYLOXY-PHENYL)-HYDRAZINE may possess anticancer properties, although further research is needed to fully understand its potential in this area. If proven effective, it could be used as a chemotherapeutic agent or in combination with other treatments to enhance cancer therapy.
Used in Antiviral Applications:
(2-BENZYLOXY-PHENYL)-HYDRAZINE may also exhibit antiviral properties, suggesting its potential use in the development of antiviral drugs. Further research is required to explore its effectiveness against various viral infections.

Upstream product

• 20012-63-9 o-(benzyloxy)aniline 
• 186663-07-0 tert-butyl (2-(benzyloxy)phenyl)carbamate 
• 186663-74-1 tert-butyl (2-hydroxyphenyl)carbamate 
• 95-55-6 2-amino-phenol 

Relevant articles and documents

Ramalin inhibits differentiation of 3T3-L1 preadipocytes and suppresses adiposity and body weight in a high-fat diet-fed C57BL/6J mice

Obesity is a serious global health problem. Natural substances that could be effective remedies for treatment of obesity, and which are relatively safe, are desired. The aim of this study was to examine the anti-obesity effect and the mechanism of ramalin in 3T3-L1 preadipocytes and high fat diet (HFD)-induced obese mice. In this study, 3T3-L1 cells were treated with various concentrations of ramalin (1, 5, and 10?μg/ml). Ramalin reduced the accumulation of intracellular lipid droplets in 3T3-L1 cells. In addition, ramalin inhibited 3T3-L1 adipocyte differentiation by blocking adipogenic gene expression including CCAAT enhancer binding proteins (C/EBPs), peroxisome proliferator-activated receptors γ (PPARγ), adipocyte fatty acid-binding protein (aP2), and leptin. The suppression of adipogenesis by ramalin was mediated through the inhibition of MAPK pathways. Ramalin also reduced the secretion of TNF-α and IL-6 in 3T3-L1 adipocytes. Oral administration of ramalin (50 and 100?mg/kg) to HFD-fed mice reduced body weight gain and abdominal fat accumulation without changes in food intake. Ramalin also attenuated organ weight and basal serum level by inhibiting Iiver X receptors (LXRs), sterol regulatory element-binding protein-1c (SREBP-1c), and lipoprotein lipase (LPL) mRNA expression in HFD-fed mice. Taken together, these results indicate that ramalin inhibits adipogenesis in 3T3-L1 preadipocytes and prevents HFD-induced obesity. The present study also provides insight into the mechanisms underlying the anti-obesity activity of ramalin and suggests that ramalin has the potential to prevent obesity.

Synthesis of aspidodispermine via pericyclic framework reconstruction

A divergent approach to the pyrroloquinoline scaffold as present in the class of Aspidosperma alkaloids was developed. As a case study, abundant and renewable nicotinic acid was transformed via pericyclic framework reconstruction into aspidodispermine, a unique member of pyrroloquinoline alkaloids. The sequence comprises a [2 + 2]-photocycloaddition, a Ramberg-B?cklund contraction, and a strain-promoted formal electrocyclic rearrangement of a bicyclo[2.2.0]hexene and is potentially extendable to pyrroloindole scaffolds as present in the ibophyllidine alkaloids.

Novel Compound - 827

The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases, including cathepsins B, K, C, F, H, L, O, S, W and X. Of particular interest are diseases associated with Cathepsin K.